

antitrust plaintiffs to actual damages under specified circumstances. Specifically, Advanced Design Consulting USA, Inc., Lansing, NY; CheyTac USA, Nashville, GA; CoorsTek, Inc., Golden, CO; CS Squared, LLC, Fairfax, VA; Digital to Definitive, LLC, Austin, TX; Florida Turbine Technologies, Inc., Jupiter, FL; GPS Source, Inc., Pueblo West, CO; II-VI Optical Systems, Inc., Murrieta, CA; Karagozian and Case, Inc., Glendale, CA; MILSPRAY, LLC, Lakewood, NJ; MTA, Inc., Huntsville, AL; Peregrine Technical Solutions, LLC, Yorktown, VA; QED Systems, LLC, Aberdeen Proving Ground, MD; R2C Support Services, Huntsville, AL; Radiance Technologies, Inc., Huntsville, AL; Scientia, LLC, Bloomington, IN; Selective Intellect, LLC, Livingston, NJ; and Technology Management Group, Inc., King George, VA, have been added as parties to this venture.

Also, OPTRA, Inc., Topsfield, MA; Orion Munitions Development, LLC, Gladstone, MO; and Trust Automation, Inc., San Luis Obispo, CA, have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and NAC intends to file additional written notifications disclosing all changes in membership.

On May 2, 2000, NAC filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on June 30, 2000 (65 FR 40693).

The last notification was filed with the Department on May 31, 2016. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on July 6, 2016 (81 FR 44044).

Patricia A. Brink,

Director of Civil Enforcement, Antitrust Division.

[FR Doc. 2016-22591 Filed 9-19-16; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical Technology Enterprise Consortium

Notice is hereby given that, on August 19, 2016, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Medical Technology Enterprise Consortium (“MTEC”) has

filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Specifically, A.G.M. Biological Products Development LTD, Nes Ziona, ISRAEL; AbViro, LLC, Bethesda, MD; Actuated Medical, Inc., Bellefonte, MD; applied Medical Device Institute (aMDI) GVSU, Grand Rapids, MI; Aptus, LLC, Clemson, SC; ARMR Systems, Snellville, GA; Axonova Medical, LLC, Philadelphia, PA; Battelle Memorial Institute, Columbus, OH; BioBridge Global, San Antonio, TX; Brown University, Providence, RI; Combat Wounded Veteran Challenge, Inc., Saint Petersburg, FL; DigitalDerm, Inc., Columbia, SC; GeoVax, Inc., Smyrna, GA; Health Research, Inc./Wadsworth Center, Menands, NY; IDIQ Inc., Fallbrook, CA; INCELL Corporation, LLC, San Antonio, TX; Indiana University, Indianapolis, IN; KIYATEC, Inc., Greenville, SC; Longeveron, LLC, Miami, FL; Lynntech, Inc., College Station, TX; MetArmor, Inc., Glen Garden, NJ; NGT-VC 2021 Limited Partnership (NGT3), Nazareth, ISRAEL; Northwestern University, Evanston, IL; Organovo, Inc., San Diego, CA; Propagenix, Inc., Rockville, MD; RhythmLink International, LLC, Columbia, SC; Scientific & Biomedical Microsystems, LLC (SBM), Glen Burnie, MD; Strategic Marketing Innovations, Inc., Washington, DC; Tonix Pharmaceuticals, Inc., New York, NY; University of California-Irvine, Irvine, CA; University of Cincinnati, Department of Surgery, Cincinnati, OH; University of Maryland-Baltimore, Baltimore, MD; and Virtech Bio, LLC, New York, NY, have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MTEC intends to file additional written notifications disclosing all changes in membership.

On May 9, 2014, MTEC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on June 9, 2014 (79 FR 32999).

The last notification was filed with the Department on March 15, 2016. A notice was published in the **Federal**

Register pursuant to Section 6(b) of the Act on April 14, 2016 (81 FR 22119).

Patricia A. Brink,

Director of Civil Enforcement, Antitrust Division.

[FR Doc. 2016-22586 Filed 9-19-16; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Members of SGIP 2.0, Inc.

Notice is hereby given that, on August 10, 2016, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Members of SGIP 2.0, Inc. (“MSGIP 2.0”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Red Hat, Inc., Raleigh, NC; and Think Energy, Houston, TX, have been added as parties to this venture.

Also, American Public Power Association (APPA), Washington, DC; ARC Informatique, Serves, FRANCE; Cornice Engineering, Inc., Grand Canyon, AZ; Elster Solutions, Raleigh, NC; GridIntellect LLC, Madison, AL; LocalGrid Technologies, Mississauga, CANADA; Milbank Manufacturing Co., Kansas City, MO; National Instruments, Austin, TX; Nikos Hatzigiorgiou Technical Office Consultants, Athens, GRECE; and Utilities Telecom Council, Inc., Washington, DC, have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MSGIP 2.0 intends to file additional written notifications disclosing all changes in membership.

On February 5, 2013, MSGIP 2.0 filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on March 7, 2013 (78 FR 14836).

The last notification was filed with the Department on April 12, 2016. A notice was published in the **Federal**

Register pursuant to Section 6(b) of the Act on May 18, 2016 (81 FR 31259).

Patricia A. Brink,

Director of Civil Enforcement, Antitrust Division.

[FR Doc. 2016-22590 Filed 9-19-16; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: Patheon API Manufacturing, Inc.

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before November 21, 2016.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (“Deputy Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on January 13, 2016, Patheon API Manufacturing, Inc., 309 Delaware Street, Building 1106, Greenville, South Carolina 29605 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Schedule
Marihuana (7360)	I
Tetrahydrocannabinols (7370)	I

Controlled substance	Schedule
Noroxymorphone (9668)	II

The company plans to manufacture the above-listed controlled substances as Active Pharmaceutical Ingredient (API) for clinical trials.

In reference to drug codes 7360 (marihuana), and 7370 (THC), the company plans to bulk manufacture these drugs as synthetics. No other activities for these drug codes are authorized for this registration.

Dated: September 12, 2016.

Louis J. Milione,

Deputy Assistant Administrator.

[FR Doc. 2016-22526 Filed 9-19-16; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Importer of Controlled Substances Application: R & D Systems, Inc.

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before October 20, 2016. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before October 20, 2016.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/ODW, 8701 Morrisette Drive, Springfield, Virginia 22152. Comments and requests for hearing on applications to import narcotic raw material are not appropriate. 72 FR 3417 (January 25, 2007).

SUPPLEMENTARY INFORMATION: The Attorney General has delegated her

authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (“Deputy Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on April 4, 2015, R & D Systems, Inc., 614 McKinley Place NE., Minneapolis, Minnesota 55413 applied to be registered as an importer of the following basic classes of controlled substances:

Controlled substance	Schedule
Mephedrone (4-Methyl-N-methylcathinone) (1248).	I
JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl) indole) (7118).	I
CP-47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol] (7297).	I
Marihuana (7360)	I
Tetrahydrocannabinols (7370)	I
4-Bromo-2,5-dimethoxyamphetamine (7391).	I
3,4-Methylenedioxymethamphetamine (7405).	I
Dimethyltryptamine (7435)	I
Psilocyn (7438)	I
Pentobarbital (2270)	II
Phencyclidine (7471)	II
Cocaine (9041)	II

The company plans to manufacture bulk active pharmaceutical controlled substances for distribution to its customers for analytical purposes.

In reference to drug codes 7360 and 7370, the company plans to import a synthetic cannabidiol and a synthetic tetrahydrocannabinol. No other activity for these drug codes is authorized for this registration.

Dated: September 12, 2016.

Louis J. Milione,

Deputy Assistant Administrator.

[FR Doc. 2016-22525 Filed 9-19-16; 8:45 am]

BILLING CODE 4410-09-P